Subscribe to RSS
Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!Funding N. reports research grants from Dr. Reddy’s Laboratories Inc, Amgen, Sanofi India Ltd., Intas Pharmaceuticals and Astra Zeneca Pharma India Ltd., outside the submitted work. K.P. reports grants from Biocon Ltd, grants from Dr. Reddy’s Laboratories Inc, grants from Fresenius Kabi India Pvt Ltd, grants from Alkem Laboratories, grants from Natco Pharma Ltd, grants from BDR Pharmaceuticals Intl Pvt Ltd, grants from Roche Holding AG, outside the submitted work. All grants were paid to the institution.
Objective Earlier studies have shown that chemoradiation (CTRT) has benefits in the head-and-neck cancer, but how far it is true for oral cavity subset that has not been exactly explored. Keeping the null hypothesis as CTRT has no benefit in oral cavity cancer, we studied the outcome of patients undergoing chemoradiation in unresectable oral cavity cancers. The aim of this study is to study whether overall survival (OS) increases with chemoradiation in unresectable oral cavity cancers.
Patients and Methods Between December 2014 and February 2017, 23 patients aged 18 years and above were planned chemoradiation for unresectable oral cavity cancer and were included for this analysis.
Results The median age of patients was 43 years and all patients were addicted to tobacco. In total, 12 of 23 (52%) completed CTRT. One patient (1/23) was alive at the time of final analysis with median OS of 5.83 (2.73–9.60) months. The median progression free survival and OS in patients who completed chemoradiation were 6.42 months (95% confidence interval [CI]: 3.67–10.53) and 8.9 months (95% CI: 4.4–23.07), respectively.
Conclusion CTRT has a limited role in unresectable oral cancers.
12 June 2021 (online)
© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Kekatpure V, Kuriakose MA. Oral Cancer in India: Learning from Different Populations. Cancer Prevention 2010
- 2 Sankaranarayanan R, Ramadas K, Thomas G. et al. Trivandrum Oral Cancer Screening Study Group. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005; 365 (94/75) 1927-1933
- 3 GLOBOCAN. The Global Cancer Observatory. GLOBOCAN. Available at: https://gco.iarc.fr/. Accessed 2018
- 4 Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132 (05) 1133-1145
- 5 NCCN. Guidelines Version 2. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 2018
- 6 Grégoire V, Lefebvre JL, Licitra L, Felip E. On behalf of the EHNS-ESMO-ESTRO guidelines working group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: 184-186
- 7 Patil VM, Prabhash K, Noronha V. et al. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol 2014; 50 (10) 1000-1004
- 8 Joshi A, Patil VM, Noronha V. et al. Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers?. Indian J Cancer 2013; 50 (04) 349-355
- 9 Patil VM, Kane S, Noronha V. et al. NACT in locally advanced oral cancers: does HPV make a difference?. J Clin Oncol 2015; 33 (Suppl. 15) e17068-e8
- 10 Noronha V, Patil VM, Joshi A. et al. Induction chemotherapy in technically unresectable locally advanced carcinoma of maxillary sinus. Chemother Res Pract 2014; 2014: 487872
- 11 Patil VM, Noronha V, Joshi A. et al. Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference?. Indian J Cancer 2013; 50 (01) 1-8
- 12 Iyer NG, Tan DS, Tan VK. et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer 2015; 121 (10) 1599-1607
- 13 Nair MK, Sankaranarayanan R, Padmanabhan TK. Evaluation of the role of radiotherapy in the management of carcinoma of the buccal mucosa. Cancer 1988; 61 (07) 1326-1331
- 14 Stenson KM, Kunnavakkam R, Cohen EE. et al. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope 2010; 120 (01) 93-99
- 15 Cheraghlou S, Kuo P, Mehra S, Yarbrough WG, Judson BL. Untreated oral cavity cancer: long-term survival and factors associated with treatment refusal. Laryngoscope 2018; 128 (03) 664-669